The U.S. Food and Drug Administration (FDA) has approved the first generic versions of GILOTRIF (afatinib) tablets, marking an important milestone in expanding access to targeted therapy for patients with specific forms of non-small cell lung cancer (NSCLC). The approval covers generic afatinib tablets manufactured by Apotex Inc. and Hetero Labs Limited Unit V.
Afatinib is an oral tyrosine kinase inhibitor (TKI) indicated for the first-line treatment of patients with metastatic NSCLC whose tumors harbor susceptible epidermal growth factor receptor (EGFR) mutations, as identified by an FDA-approved diagnostic test. It is also approved for the treatment of patients with metastatic squamous NSCLC whose disease has progressed after platinum-based chemotherapy.
According to the FDA, first generic approvals are considered a public health priority because they increase market competition, improve patient access, and can help reduce treatment costs. The agency gives priority review to such applications to make more affordable medicines available as soon as possible.
The newly approved abbreviated new drug applications (ANDAs) include, Apotex Inc. – ANDA 210725 and Hetero Labs Limited Unit V – ANDA 210750; Both products are approved as therapeutically equivalent generic versions of GILOTRIF (afatinib) tablets, originally developed by Boehringer Ingelheim.
Originally approved by the FDA in 2013, GILOTRIF became one of the first irreversible EGFR inhibitors for the treatment of EGFR mutation-positive metastatic NSCLC. The availability of generic alternatives is expected to improve affordability and broaden patient access to this targeted cancer therapy in the United States.
The approval also highlights the growing role of generic manufacturers, including India-based Hetero Labs, in supplying complex oncology medicines to the U.S. market through the FDA’s abbreviated approval pathway.
